Cure rate of high dose omeprazole and amoxicillin therapy for treatment-resistant Helicobacter pylori infection [4]

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 4, 2005, Pages 663-664

  Viiala, Charlie H ^a   Windsor, Helen M ^b   Marshall, Barry J ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE;

BACTERIUM ISOLATION; CLINICAL ARTICLE; DRUG MEGADOSE; DYSPEPSIA; ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; INFECTION RESISTANCE; LETTER; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 19944416211     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03833.x     Document Type: Letter

References (5)

1. Ellenrieder V, Boeck W, Richter CW, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand. J. Gastroenterol. 1999; 34: 750-56.
2. Sharma BK, Santana IA, Wood EC et al. Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole. BMJ 1984; 289: 717-19.
3. Kita T, Sakaeda T, Aoyama N et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol. Pharm. Bull. 2002; 25: 923-7.
4. Tanigawara Y, Aoyama N, Kita T et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 1999; 66: 528-34.
5. Furuta T, Shirai N, Xiao F et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003; 50: 2274-8.